Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epinephrine self-injectable - kaleo

Next Previous
X
Search
Drug Profile

Epinephrine self-injectable - kaleo

Alternative Names: Allerject; Auvi-Q; e-cue

Latest Information Update: 05 Aug 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intelliject
  • Developer kaleo; Sanofi
  • Class Anti-infectives; Antiallergics; Antiasthmatics; Bronchodilators; Catecholamines; Ethanolamines; Skin disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaphylaxis; Hypersensitivity

Most Recent Events

  • 02 Aug 2022 Epinephrine self-injectable licensed to Valeo Pharma for commercialisation in Canada
  • 29 Aug 2018 Kaleo plans to reintroduce epinephrine injection (AUVI-Q®) in Canada by 7th September 2018.
  • 26 Apr 2018 The US FDA approves sNDA application for epinephrine auto-injector 0.1mg in Anaphylaxis (patients weighing 16.5 to 33 pounds)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top